Microcap Ledger Incannex Healthcare Inc. $IXHL
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Norwest Nsw
- Fiscal year end
- June 30
- Shares outstanding
- 12,544,627 [10-K 2026-09-25]
What the company doesAI summary of filing
Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company developing oral fixed-dose combination therapies and psychedelic-assisted treatments for serious chronic conditions. The company's lead programs are IHL-42X, a combination of dronabinol and acetazolamide for obstructive sleep apnea, which completed Phase 2 testing and received FDA Fast Track designation in December 2025; PSX-001, an oral synthetic psilocybin treatment combined with psychological therapy for generalized anxiety disorder, which completed Phase 2 testing in August 2025; and IHL-675A, a combination of cannabidiol and hydroxychloroquine for inflammatory conditions, currently in early-stage development after a Phase 2 trial was terminated. The company is pre-revenue and advancing its lead candidates through clinical development with plans to pursue FDA approval via New Drug Applications. [10-K 2026-09-25]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| FY ended Jun 2026 | $0.00 | −$19.30M | −$12.87M | $67.71M | [10-K 2026-09-25] |
| FY ended Jun 2025 | $86.0K | −$46.88M | −$12.51M | $15.04M | [10-K 2026-09-25] |
- Quarterly cash burn
- −$3.22M
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-12 | 17,642,832 | [10-Q 2024-11-14] |
| 2025-02-14 | 17,859,708 | [10-Q 2025-02-14] |
| 2025-05-13 | 29,433,798 | [10-Q 2025-05-15] |
| 2025-09-28 | 347,705,507 | [10-K 2025-09-29] |
| 2025-11-14 | 346,225,507 | [10-Q 2025-11-14] |
| 2026-02-13 | 358,329,368 | [10-Q 2026-02-13] |
| 2026-05-15 | 11,964,554 | [10-Q 2026-05-15] |
| 2026-09-24 | 12,544,627 | [10-K 2026-09-25] |
- Shelf registration
- S-3 filed 2025-03-24; declared effective 2025-04-28 [S-3 2025-03-24]
Listing status
Current status: 5 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-03-17. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-03-17 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-03-17] |
| 2025-10-22 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-10-22] |
| 2025-06-13 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-06-13] |
| 2025-04-25 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-04-25] |
| 2025-01-10 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-01-10] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2025-11-14 | Valentine Troy | grant | 11,302,608 | — | [4 2025-11-14] |
| 2025-11-14 | Clark Robert | grant | 1,686,956 | — | [4 2025-11-14] |
| 2025-11-14 | Widdows Peter | grant | 1,686,956 | — | [4 2025-11-14] |
| 2025-11-14 | Swan Joseph | grant | 869,565 | — | [4 2025-11-14] |
| 2025-11-14 | Latham Joel | grant | 22,608,692 | — | [4 2025-11-14] |
| 2025-11-14 | Anastassov George | grant | 1,686,956 | — | [4 2025-11-14] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-25 | 10-K | Annual report |
| 2026-09-09 | 8-K | Regulation FD disclosure |
| 2026-08-25 | 8-K | Regulation FD disclosure |
| 2026-08-14 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-11 | 8-K | Regulation FD disclosure |
| 2026-07-23 | 8-K | Regulation FD disclosure |
| 2026-06-25 | 8-K | Regulation FD disclosure |
| 2026-06-10 | 8-K | Regulation FD disclosure |
| 2026-06-09 | 8-K | Regulation FD disclosure |
| 2026-05-15 | 10-Q | Quarterly report |
| 2026-05-14 | 8-K | Regulation FD disclosure |
| 2026-05-12 | 8-K | Regulation FD disclosure |
Alerts for $IXHL
Email me when Incannex Healthcare Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.